Four Days Left To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before The Ex-Dividend Date
Four Days Left To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before The Ex-Dividend Date
Jacobson Pharma Corporation Limited (HKG:2633) is about to trade ex-dividend in the next 4 days. The ex-dividend date occurs one day before the record date which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. In other words, investors can purchase Jacobson Pharma's shares before the 3rd of September in order to be eligible for the dividend, which will be paid on the 4th of October.
雅各臣科研制药有限公司(HKG:2633)即将在接下来的4天内开多分红派息。分红除权日发生在纪录日的前一天,纪录日是股东需要在公司账簿上登记以便领取分红的日子。分红除权日很重要,因为每次股票的买卖交易至少需要两个工作日来结算。换句话说,投资者可以在9月3日之前买入雅各臣科研制药的股票,以符合获得分红的资格,分红将于10月4日支付。
The company's next dividend payment will be HK$0.03 per share, on the back of last year when the company paid a total of HK$0.055 to shareholders. Last year's total dividend payments show that Jacobson Pharma has a trailing yield of 9.2% on the current share price of HK$0.60. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. We need to see whether the dividend is covered by earnings and if it's growing.
公司的下一个分红支付将是每股0.03港元,在去年公司向股东支付了总额为0.055港元的情况下。去年的总分红显示雅各臣科研制药目前每股0.60港元的股价有着9.2%的滚动收益率。分红对于长期股东投资回报是一个重要贡献者,但前提是分红持续支付。我们需要看分红是否有盈利覆盖以及是否在增长。
Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Jacobson Pharma paid out more than half (57%) of its earnings last year, which is a regular payout ratio for most companies. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Fortunately, it paid out only 26% of its free cash flow in the past year.
分红通常由公司利润支付,所以如果一家公司支付的分红超过了其盈利,那么它的股息通常面临更大的被削减风险。雅各臣科研制药去年支付了超过一半(57%)的盈利,这是大多数公司的常规支付比率。然而,现金流通常比利润更重要,用于评估分红的持续性,所以我们应该始终检查公司是否产生足够的现金来支付其分红。幸运的是,它在过去一年中仅支付了其自由现金流的26%。
It's positive to see that Jacobson Pharma's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.
看到雅各臣科研制药的分红既获利盖得住也被现金流覆盖,这通常是分红持续支付的迹象,而较低的支付比率通常意味着在分红被削减之前有更大的安全边际。
Click here to see how much of its profit Jacobson Pharma paid out over the last 12 months.
点击这里查看雅各臣科研制药过去12个月中支付了多少利润。
![1724972184594](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240830/43089350-0-bdc433f2fd59a62b210ce7638bff8291.webp/bigjpg)
Have Earnings And Dividends Been Growing?
收益和股息一直在增长吗?
When earnings decline, dividend companies become much harder to analyse and own safely. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. Readers will understand then, why we're concerned to see Jacobson Pharma's earnings per share have dropped 5.8% a year over the past five years. Such a sharp decline casts doubt on the future sustainability of the dividend.
当盈利下滑,分红公司会变得更难分析和安全拥有。投资者喜欢分红,所以如果盈利下降并且分红减少,预计股票会大幅抛售。读者将理解我们为什么担心雅各臣科研制药过去五年每股收益下降了5.8%。如此大幅跌幅对分红的未来可持续性产生了怀疑。
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. In the past eight years, Jacobson Pharma has increased its dividend at approximately 17% a year on average. Growing the dividend payout ratio while earnings are declining can deliver nice returns for a while, but it's always worth checking for when the company can't increase the payout ratio any more - because then the music stops.
衡量一家公司的分红前景的另一种关键方法是衡量其历史分红增长率。在过去八年中,雅各臣科研制药的分红每年平均增长约17%。在盈利下降的情况下增加分红支付比率可能会带来一段时间不错的回报,但是值得检查的是当公司无法再增加分红支付比率时,音乐停止了。
The Bottom Line
还有一件事需要注意的是,我们已经确定了上海医药的2个警告信号,了解这些信号应该成为你的投资过程的一部分。
Is Jacobson Pharma worth buying for its dividend? We're not enthused by the declining earnings per share, although at least the company's payout ratio is within a reasonable range, meaning it may not be at imminent risk of a dividend cut. While it does have some good things going for it, we're a bit ambivalent and it would take more to convince us of Jacobson Pharma's dividend merits.
雅各臣科研制药是否值得购买分红?我们对每股盈利的下降并不感到兴奋,尽管公司的分红支付比率处于合理范围内,这意味着它可能不会立即面临分红削减的风险。虽然它有一些优点,但我们对雅各臣科研制药的分红价值还持有矛盾态度,需要更多的说服力才能让我们相信它。
If you're not too concerned about Jacobson Pharma's ability to pay dividends, you should still be mindful of some of the other risks that this business faces. Our analysis shows 3 warning signs for Jacobson Pharma that we strongly recommend you have a look at before investing in the company.
如果您不太担心雅各臣科研制药支付分红的能力,仍应注意该业务面临的其他风险。我们的分析显示了雅各臣科研制药存在3个警告信号,强烈建议您在投资该公司之前查看这些警告信号。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
一般来说,我们不建议仅仅购买第一个股息股票。下面是一个经过策划的有趣的、股息表现良好的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。